Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Vanda Pharmaceuticals in a report on Monday, December 23rd.

Vanda Pharmaceuticals Trading Down 3.3 %

NASDAQ:VNDA opened at $4.38 on Friday. The stock has a market capitalization of $255.39 million, a PE ratio of -15.64 and a beta of 0.77. Vanda Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $6.75. The firm has a fifty day simple moving average of $4.87 and a 200 day simple moving average of $5.06.

Insider Buying and Selling at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals in the second quarter valued at about $39,000. ORG Wealth Partners LLC bought a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at about $40,000. China Universal Asset Management Co. Ltd. grew its position in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $75,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $84,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.